Drug General Information (ID: DDI4G7TXBO)
  Drug Name Gatifloxacin Drug Info Insulin glulisine Drug Info
  Drug Type Small molecule Hormones
  Therapeutic Class Antiinfective Agents Antidiabetic Agents
  Structure

 Mechanism of Gatifloxacin-Insulin glulisine Interaction (Severity Level: Major)
     Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Gatifloxacin Insulin glulisine
      Mechanism 1 Hypoglycemic effects Antidiabetic agent
      Key Mechanism Factor 1
Factor Name Hypoglycemia
Factor Description Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating.
      Mechanism Description
  • Increased risk of hypoglycemia by the combination of Insulin glulisine and Gatifloxacin 
     Antagonize the effect of antidiabetic agents Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Gatifloxacin Insulin glulisine
      Mechanism 2 Hyperglycemia Antidiabetic agent
      Key Mechanism Factor 2
Factor Name Antidiabetic agents
Factor Description The hypoglycemic effect of antidiabetes may be reduced, leading to higher blood glucose, increased blood glucose fluctuations, and the possibility of hyperglycemic complications
      Mechanism Description
  • Antagonize the effect of Insulin glulisine when combined with Gatifloxacin 
      Mechanism 3 Hyperglycemic effects Antidiabetic agent
      Key Mechanism Factor 3
Factor Name Antidiabetic agents
Factor Description The hypoglycemic effect of antidiabetes may be reduced, leading to higher blood glucose, increased blood glucose fluctuations, and the possibility of hyperglycemic complications
      Mechanism Description
  • Antagonize the effect of Insulin glulisine when combined with Gatifloxacin 

Recommended Action
      Management The use of gatifloxacin is contraindicated in patients with diabetes mellitus. Other quinolones may be safer alternatives in such patients, although all quinolones should be used with caution. Blood glucose should be closely monitored whenever quinolones are prescribed to patients receiving insulin or other antidiabetic agents, especially if they are elderly or have renal impairment. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.

References
1 Greenberg AL, Decerbo M, Fan J "Gatifloxacin therapy associated with hypoglycemia." Clin Infect Dis 40 (2005): 1210-1. [PMID: 15791528]
2 Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC "Gatifloxacin-induced hyperglycemia." Ann Intern Med 141 (2004): 968-9. [PMID: 15611500]
3 Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006): 1352-61. [PMID: 16510739]